News Opinion Off Script Evoque and Patisiran: A Tale of Two Regulatory Journeys Sanjay Kaul, MD March 29, 2024
News Features ‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry Michael O'Riordan January 10, 2020
News Daily News FDA Provides Update on Tainted ARB Investigation, With New Impurity Found Todd Neale March 04, 2019
News Daily News Lack of Short-term Cancer Risk With Tainted Valsartan ‘Reassuring’ Todd Neale September 13, 2018
News Daily News FDA Recalls Valsartan-Containing Drugs After Detection of Carcinogen Michael O'Riordan July 16, 2018